Alzamend Neuro, Inc. (ALZN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Alzamend Neuro, Inc. (ALZN) closed at USD 1.35 on 2026-10-14, a change of -42.8 % over the past year, with a market capitalization of USD 6.18M.

Alzamend Neuro, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Alzamend Neuro, Inc. key figures

Previous close

USD 1.35 (2026-10-14)

1-year change

-42.8 %

Market cap

USD 6.18M

Enterprise value

USD -1.41M

P/E ratio (trailing)

-0.58

P/E ratio (forward)

-1.47

EPS (trailing)

-2.20

EPS (forward)

-0.87

PEG ratio

n/a

Price to book

1.06

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.09

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Alzamend Neuro, Inc. and compare it with other stocks.